Chronic renal failure following liver transplantation: A retrospective analysis

Transplantation

Volumn 66, Issue 1, 1998, Pages 59-66

  Fisher, Neil C ^a   Nightingale, Peter G ^b   Gunson, Bridget K ^a   Lipkin, Graham W ^a   Neuberger, James M ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY; KIDNEY FAILURE, CHRONIC; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TIME FACTORS;

EID: 0032528030     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199807150-00010     Document Type: Article

References (25)

1. Anonymous. A randomized clinical trial of cyclosporine in cadaveric renal transplantation: analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med 1986; 314: 1219.
2. Iwatsuki S, Starzl TE, Todd S, et al. Experience in 1000 liver transplants under cyclosporin-steroid therapy: a survival report. Transplant Proc 1988; 20: 498.
3. Feutren G, Miller C. Low predictive value of cyclosporine level for efficacy or renal dysfunction in psoriasis and idiopathic nephrotic syndrome. Transplant Proc 1990; 22: 1299.
4. Bach JF, Feutren G, Noel LH, et al. Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels. Transplant Proc 1990; 22: 1296.
5. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
6. Hollander AAMJ, van Saase JLCM, Kootte AMM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610.
7. Monsour HP, Wood RP, Dyer CH, Galati JS, Ozaki CF, Clark JH. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 1995; 15: 123.
8. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein RM, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59: 361.
9. Nochy D, Druet D, Bariety J. IgA nephropathy in chronic liver disease. Contrib Nephrol 1984; 40: 268.
10. Gunson BK, Jones SR, Buckels JAC, Jain AB, McMaster P. Liver transplantation in Birmingham: use of cyclosporine - clinical correlations with drug measurements. Transplant Proc 1990; 22: 1312.
11. Keating J, Neuberger J, Clarke M, et al. Renal function and morphology in cyclosporin A-treated liver transplant recipients. Clin Transplant 1988; 2: 110.
12. Palestine AG, Austin HA, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314: 1293.
13. Singh N, Gayowski T, Marino IR. Haemolytic uremic syndrome in solid-organ transplant recipients. Transpl Int 1996; 9: 68.
14. Paul A, Levy GA, Greig PD. Balancing cyclosporine A nephrotoxicity and rejection late after adult liver transplantation. Transplant Proc 1993; 25: 2664.
15. Navis G, de Zeeuw D, de Jong PE. ACE inhibitors: panacea for progressive renal disease? [Editorial]. Lancet 1997; 349: 1852.
16. Azoulay D, Lemoine A, Dennison A, et al. Incidence of adverse reactions to cyclosporine after liver transplantation is predicted by the first blood level. Hepatology 1993; 18: 1123.
17. O'Grady JG, Forbes A, Rolles K, Calne RY, Williams R. An analysis of cyclosporine efficacy and toxicity after liver transplantation. Transplantation 1988; 45: 575.
18. Klompmaker IJ, Homan van der Heide JJ, Tegzess AM, et al. Effects of cyclosporine A withdrawal on renal function and renal stimulation in liver transplant patients treated with triple-drug immunosuppression for over 2 years. Nephrol Dial Transplant 1994; 9: 1629.
19. Sandborn WJ, Hay JE, Porayko MK, et al. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19: 925.
20. Devlin J, Slapak G, Portmann B, Williams R. Immunosuppression withdrawal in long-term liver transplant recipients. Hepatology 1994; 20: 124A.
21. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423.
22. Lipsky JJ. Drug profile: mycophenolate mofetil. Lancet 1996; 348: 1357.
23. Randhawa PS, Shapiro R, Jordan ML, Starzl TE, Demetris AJ. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison with cyclosporine. Am J Surg Pathol 1993; 17: 60.
24. Platz KP, Mueller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation: a comparison between cyclosporine and FK506. Transplantation 1994; 58: 170.
25. Sollinger HW, U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.